Genomic Vision

Genomic Vision P/B

The P/B (Price-to-Book Ratio) of Genomic Vision (GV.PA) as of Oct 23, 2026 is -0.54. In the previous year, P/B (Price-to-Book Ratio) was 0.23 — a change of -338.17% (lower).

P/B

-0.54

YoY

-338.17%

Last updated:

P/B (Price-to-Book Ratio) of Genomic Vision is 2022 -0.54 . P/B (Price-to-Book Ratio) of Genomic Vision was 2021 0.23 . It decreases by -338.17% lower compared to the previous year.

The Genomic Vision P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2015
0.04 EUR
Jan 1, 2016
0.07 EUR
Jan 1, 2017
0.19 EUR
Jan 1, 2018
0.17 EUR
Jan 1, 2019
0.22 EUR
Jan 1, 2020
0.22 EUR
Jan 1, 2021
0.23 EUR
Jan 1, 2022
-0.54 EUR
The Genomic Vision P/B history
YEARP/BYoY
-0.54-338.17%
0.23+1.73%
0.22+3.33%
0.22+29.13%
0.17-9.84%
0.19+167.10%
0.07+83.16%
0.04+23.50%
0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Vision stock

P/B (Price-to-Book Ratio) of Genomic Vision is -0.54 in 2022.

P/B (Price-to-Book Ratio) of Genomic Vision changed from 0.23 to -0.54, representing a -338.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Genomic Vision with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Genomic Vision

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Genomic Vision